Clinical trial
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory…
NCT02576990 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT02576990 |
|---|---|
| Title | Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma or Relapsed or Refractory Richter Syndrome (MK-3475-170/KEYNOTE-170) |
| Official title | A Phase II Study of Pembrolizumab (MK-3475) in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) or Relapsed or Refractory Richter Syndrome (rrRS) |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Mediastinal Large B-cell Lymphoma, Richter Syndrome |
| Intervention type | Biological |
| Interventions | Pembrolizumab |
| Enrollment | 80 |
| Start date | Dec 2, 2015 |
| Primary completion | May 28, 2019 |
| Completion | Oct 23, 2020 |
| First posted | Oct 15, 2015 |
| Last update posted | Jul 27, 2023 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: